Press release
Cyramza (Ramucirumab) Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis
Cyramza (Ramucirumab)
What Is the Cyramza (Ramucirumab) Market Size and Projected Growth Rate?
The market size for cyramza (ramucirumab) has demonstrated solid growth in the past years. The market is projected to expand from $1,232.96 million in 2024 to $1,314.14 million in 2025, with a compound annual growth rate (CAGR) of 6.6%. The growth during the historic period is linked to the rising occurrence of colorectal cancer, elevated air pollution levels, increasing cases of malignant diseases, tobacco use and smoking, as well as a growing number of elderly patients.
The market for cyramza (ramucirumab) is projected to experience robust growth in the coming years, reaching a value of $1,686.33 million in 2029 with a CAGR of 6.4%. The market's expansion during the forecast period can be attributed to factors such as an upsurge in clinical trials, increased cancer screening initiatives, growing demand for treatment, rising patient numbers, and lifestyle changes. The forecast period will also witness trends such as widened use of ramucirumab, approvals from the FDA, focus on customized medicine, increased uptake of combination treatments, and innovation in products.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19894
What Are the Major Segments in the Cyramza (Ramucirumab) Market?
The cyramza (ramucirumab) market covered in this report is segmented -
1) By Type: 100mg/Box; 500mg/Box
2) By Application: Advanced Gastric Cancer; GEJ Adenocarcinoma; Non-small Cell Lung Carcinoma; Metastatic Colorectal Cancer (mCRC); Hepatocellular Carcinoma (HCC)
3) By End-User: Hospitals; Cancer Treatment Centers; Ambulatory Surgical Centers; Research Institutes
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19894&type=smp
What Are The Driving Cyramza (Ramucirumab) Market Evolution?
The increasing prevalence of cancer is likely to stimulate the expansion of the Cyramza (ramucirumab) market. Unregulated cell growth spreading to different body parts is the main hallmark of cancer, which covers numerous diseases. The mounting cases of cancer are primarily due to factors like an aging demographic, lifestyle decisions, environmentally induced exposures, enhanced detection approaches, and genetic susceptibilities. Cyramza (ramucirumab), a cancer therapeutic drug, works by inhibiting the vascular endothelial growth factor receptor 2 (VEGFR-2) to restrain tumor blood vessel formation and consequently, decelerate the progression of cancer. For example, a study conducted by the Australian Institute of Health and Welfare in August 2024 projected that Australia would have approximately 209,000 new cancer cases by 2034, a substantial surge from the predicted 169,000 cases in 2024. This substantial rise is indicative of the escalating population and cancer rates. Furthermore, in 2024, it is expected that nearly 3 in every 10 deaths in the country would be as a result of cancer. Therefore, the escalating prevalence of cancer is fueling the expansion of the Cyramza (ramucirumab) market.
Which Firms Dominate The Cyramza (Ramucirumab) Market Segments?
Major companies operating in the cyramza (ramucirumab) market include Eli Lilly and Company
What Trends Are Expected to Dominate the Adlyxin (Lyxumia) Market in the Next 5 Years?
The market is primarily trending towards the creation of novel drug solutions to enhance treatment for patients with advanced or metastatic conditions. Innovative medicines for hepatocellular carcinoma, like ramucirumab, are assisting patients by aiming at specific cancer markers to decelerate tumor growth and improve survival outcomes. For instance, Innovent Biologics Inc., a Chinese biopharmaceutical firm, revealed in October 2022 that China's National Medical Products Administration (NMPA) has given approval for the additional New Drug Application (sNDA) of CYRAMZA (ramucirumab) to treat hepatocellular carcinoma (HCC, or liver cancer) in patients with an alpha-fetoprotein level of ≥400 ng/mL and have previously undergone sorafenib treatment along with CYRAMZA accompanied by paclitaxel for second-line treatment in patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma. This made it the first and only targeted drug approved for the second-line treatment of advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma in China.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/cyramza-ramucirumab-global-market-report
Which Is The Largest Region In The Cyramza (Ramucirumab) Market?
North America was the largest region in the cyramza (ramucirumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cyramza (ramucirumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Cyramza (Ramucirumab) Market?
2. What is the CAGR expected in the Cyramza (Ramucirumab) Market?
3. What Are the Key Innovations Transforming the Cyramza (Ramucirumab) Industry?
4. Which Region Is Leading the Cyramza (Ramucirumab) Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.
Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cyramza (Ramucirumab) Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis here
News-ID: 4059713 • Views: …
More Releases from The Business Research Company
Strong Growth Ahead: AC Electric Motor Market Size To Grow At Arecord 6% Cagr By …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How Big Is the AC Electric Motor Market Size Expected to Be by 2034?
The size of the AC electric motor market has seen significant expansion in past years, with projected growth from $17.30 billion in 2024 to $18.39 billion in 2025, at a compound annual growth rate (CAGR) of 6.3%. The development observed…
Mircera Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportuniti …
"The Mircera Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Mircera Market Size and Its Estimated Growth Rate?
Over recent years, we've seen considerable growth in the Mircera market. Projected figures indicate this will continue, increasing from $2,679.57 million in 2024 to…
Rising Incidence Of Inflammatory Bowel Disease Fuels Growth Of The Entyvio Marke …
"The Entyvio Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Entyvio Market Size During the Forecast Period?
The size of the Entyvio market has seen a XX (HCAGR) increase in recent times. The market, valued at $XX million in 2024, is projected…
Impact Of Rising Chronic Disease Prevalence On The Growth Of The Ceprotin (Prote …
"The Ceprotin (Protein C Concentrate) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Ceprotin (Protein C Concentrate) Market?
The market for ceprotin (protein C concentrate) has been experiencing robust growth in the past few years. It's projected to expand…
More Releases for Cyramza
Bile Duct Cancer Market To Demonstrate a Phenomenal Growth at Rising CAGR 9.2% u …
Market Research Future published a research report on Global Bile Duct Cancer Market and Provide Market analysis, size, share and future growth of industry. The Global Bile Duct Cancer Market is expected to grow at an approximate CAGR of 9.1% during the forecast period. Report provide unique information which is unavailable on any other source and forecast up to 2023
Bile duct cancer or cholangiocarcinoma is a rare form of cancer…
Bile Duct Cancer Market Ready to Hit at a CAGR of 9.2% by 2023 | Pfizer, F. Hoff …
Market Research Future published a research report on Global Bile Duct Cancer Market and Provide Market analysis, size, share and future growth of industry. The Global Bile Duct Cancer Market is expected to grow at an approximate CAGR of 9.1% during the forecast period. Report provide unique information which is unavailable on any other source and forecast up to 2023
Bile duct cancer or cholangiocarcinoma is a rare form of cancer…
Global Gastric and Gastroesophageal Junction Adenocarcinoma Market Will Reach At …
"The Report PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments…
Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Drug Classes, C …
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (about 85% of lung cancers) and it usually grows and spreads more slowly than small cell lung cancer. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer. Non-small cell lung cancer is a major type of lung cancer, accounting about 80% to 90% of the total lung cancers, with one…
Asia-Pacific gastric cancer market set to experience strong growth to $2.7 billi …
Report Title: Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies.
The Asia-Pacific (APAC) gastric cancer market is set to rise from $1.3 billion in 2015 to $2.7 billion by 2022, at a strong compound annual growth rate of 11.4%, according to business intelligence provider GBI Research.
Gayathri Kanika, Analyst for GBI Research, states: “In line with improved diagnosis rates, the…
U.S. Non-Small Cell Lung Cancer Therapeutics Market Revenue, by Country, 2015 - …
A research study, recently published by Transparency Market Research (TMR), estimates the global non-small cell lung cancer (NSCLC) therapeutics market to expand at a healthy CAGR of 12.10% over the period from 2015 to 2023 and reach a value of US$15.1 bn by the end of the forecast period.The report, titled “Non Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 -…
